ATE523200T1 - Kombination mit sapacitibin (2'-cyano-2'-desoxy- n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosin) und einem zytotoxischen mittel - Google Patents

Kombination mit sapacitibin (2'-cyano-2'-desoxy- n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosin) und einem zytotoxischen mittel

Info

Publication number
ATE523200T1
ATE523200T1 AT07848612T AT07848612T ATE523200T1 AT E523200 T1 ATE523200 T1 AT E523200T1 AT 07848612 T AT07848612 T AT 07848612T AT 07848612 T AT07848612 T AT 07848612T AT E523200 T1 ATE523200 T1 AT E523200T1
Authority
AT
Austria
Prior art keywords
arabinofuranosyl
palmitoyl
cytosine
cyano
beta
Prior art date
Application number
AT07848612T
Other languages
English (en)
Inventor
Simon Green
Ian Fleming
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Application granted granted Critical
Publication of ATE523200T1 publication Critical patent/ATE523200T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
AT07848612T 2006-12-19 2007-12-19 Kombination mit sapacitibin (2'-cyano-2'-desoxy- n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosin) und einem zytotoxischen mittel ATE523200T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0625283.7A GB0625283D0 (en) 2006-12-19 2006-12-19 Combination
PCT/GB2007/004883 WO2008075042A1 (en) 2006-12-19 2007-12-19 Combination comprising cndac (2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosine) and a cytotoxic agent

Publications (1)

Publication Number Publication Date
ATE523200T1 true ATE523200T1 (de) 2011-09-15

Family

ID=37712386

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07848612T ATE523200T1 (de) 2006-12-19 2007-12-19 Kombination mit sapacitibin (2'-cyano-2'-desoxy- n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosin) und einem zytotoxischen mittel

Country Status (7)

Country Link
US (2) US8349792B2 (de)
EP (1) EP2101790B1 (de)
JP (1) JP5457196B2 (de)
CN (1) CN101610776A (de)
AT (1) ATE523200T1 (de)
GB (1) GB0625283D0 (de)
WO (1) WO2008075042A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3580913B2 (ja) * 1995-07-14 2004-10-27 ホーユー株式会社 染毛用塗布部洗浄用具および洗浄方法
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
PL2148676T3 (pl) 2007-04-25 2016-12-30 Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
US10226478B2 (en) 2011-04-14 2019-03-12 Cyclacel Limited Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia
CA2849708A1 (en) * 2011-09-23 2013-03-28 Celgene Corporation Romidepsin and 5 - azacitidine for use in treating lymphoma
EP2874631A1 (de) 2012-05-15 2015-05-27 Cyclacel Limited Dosierungsschema für sapacitabin und seliciclib
US11957701B2 (en) 2020-07-17 2024-04-16 Delta-Fly Pharma, Inc. Therapy and new therapeutic agent for blood cancer

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2305815A1 (de) 1973-02-07 1974-08-08 Kurt Seuberth Vorrichtung zum trennen von chirurgischen faeden
DE7304511U (de) 1973-02-07 1974-02-28 Classen M Vorrichtung zum trennen von faeden
US4904768A (en) * 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
RU2085557C1 (ru) 1991-09-30 1997-07-27 Санкио Компани Лимитед Производные нуклеозидов пиримидина или их фармацевтически приемлемые соли и способ их получения
US5720745A (en) 1992-11-24 1998-02-24 Erbe Electromedizin Gmbh Electrosurgical unit and method for achieving coagulation of biological tissue
WO1995007086A1 (en) * 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
US5599922A (en) * 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
DE4419792C1 (de) 1994-06-06 1996-02-01 Alfons Prof Dr Med Hofstetter Endoskop
JPH08291061A (ja) * 1995-04-18 1996-11-05 Tanaka Kikinzoku Kogyo Kk 抗癌剤の併用投与方法及び併用可能な抗癌剤
JPH08169825A (ja) * 1994-12-15 1996-07-02 Tanaka Kikinzoku Kogyo Kk 抗癌剤の併用投与方法及び併用可能な抗癌剤
DK0831852T3 (da) * 1995-06-07 2007-03-19 Univ Emory Nukleosider med anti-hepatitis B-virusaktivitet
NL1003503C2 (nl) * 1996-07-04 1998-01-07 Negma Steba International Dev Farmaceutische samenstelling voor orale toediening.
US5824984A (en) * 1997-03-31 1998-10-20 Morrow; John A. Portable electric wire cutter
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6403632B1 (en) * 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
US6835185B2 (en) * 1998-12-21 2004-12-28 Micrus Corporation Intravascular device deployment mechanism incorporating mechanical detachment
WO2000067760A1 (fr) 1999-05-11 2000-11-16 Sankyo Company, Limited Preparation de liposomes a base de medicaments antitumoraux liposolubles
US6462063B1 (en) * 2000-02-04 2002-10-08 Fibrogen, Inc. C-proteinase inhibitors
US20020156033A1 (en) * 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
EP1186612B1 (de) 2000-04-13 2006-11-29 Mitsui Chemicals, Inc. Verfahren zur herstellung von cytidin-derivaten
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) * 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
JP5230052B2 (ja) * 2000-05-26 2013-07-10 イデニクス（ケイマン）リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
WO2001097843A2 (en) * 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
WO2002028829A2 (en) 2000-09-25 2002-04-11 Questcor Pharmaceuticals, Inc. Peptide deformylase inhibitors
ATE491459T1 (de) 2000-10-18 2011-01-15 Pharmasset Inc Modifizierte nukleoside zur behandlung von virusinfektionen und abnormaler zellulärer proliferation
US20030124512A1 (en) * 2000-10-18 2003-07-03 Lieven Stuyver Simultaneous quantification of nucleic acids in diseased cells
JP2004538247A (ja) 2000-12-08 2004-12-24 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー セミカルバジド及びサイクリン依存キナーゼ阻害剤
JP3748536B2 (ja) 2001-02-09 2006-02-22 三共株式会社 ピリミジンヌクレオシド誘導体の結晶
US6908906B2 (en) * 2001-02-09 2005-06-21 Sankyo Company, Limited Crystalline forms of pyrimidine nucleoside derivative
US6676692B2 (en) * 2001-04-27 2004-01-13 Intek Technology L.L.C. Apparatus for delivering, repositioning and/or retrieving self-expanding stents
EP1397137B1 (de) * 2001-05-25 2009-10-14 Bristol-Myers Squibb Company Hydantion-derivate als hemmer von matrix-metalloproteinasen
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
EP1293205A1 (de) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproinsäure und deren Derivate zur Kombinationsbehandlung von Krebs beim Menschen und zur Behandlung von Tumor-Metastasen und minimaler Resterkrankung
US20030170755A1 (en) * 2001-09-26 2003-09-11 Ludwig Institute For Cancer Research Tumor-associated antigen RHAMM
WO2003039536A1 (en) 2001-11-07 2003-05-15 Yale University Enhancement of taxane-based chemotherapy by a cdk1 antagonist
US7137993B2 (en) 2001-12-03 2006-11-21 Xtent, Inc. Apparatus and methods for delivery of multiple distributed stents
JP4468617B2 (ja) * 2001-12-04 2010-05-26 デビオファーム エス．アー． 抗癌剤の併用投与方法及び併用可能な抗癌剤
US7011846B2 (en) * 2001-12-21 2006-03-14 Shire Laboratories, Inc. Oral capsule formulation with increased physical stability
US8383605B2 (en) * 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
BR0314112A (pt) * 2002-09-13 2005-07-12 Univ Virginia Commonwealth Combinação de a) n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e b) um inibidor de desacetilase de histona para o tratamento de leucemia
CA2526212C (en) 2003-05-16 2013-08-27 Hybridon, Inc. Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
US20050014716A1 (en) * 2003-05-21 2005-01-20 Wang Jin Wei Pancreatic cancer treatment
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
GB0328180D0 (en) * 2003-12-04 2004-01-07 Cyclacel Ltd Combination
WO2005115410A2 (en) 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
GB0413730D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
ITFI20040173A1 (it) 2004-08-03 2004-11-03 Protera S R L Profarmaci attivati da dna polimerasi dipendenti da rna
EP1846039A2 (de) * 2005-01-10 2007-10-24 Research Development Foundation Gezielte chimärische moleküle zur krebstherapie
TW200637870A (en) * 2005-01-31 2006-11-01 Taiho Pharmaceutical Co Ltd Novel pyrimidine nucleoside compound and salt thereof
US20060212899A1 (en) * 2005-03-17 2006-09-21 Ryan Steelberg System and method for broadcast tagging
GB0523041D0 (en) 2005-11-11 2005-12-21 Cyclacel Ltd Combination
GB0526419D0 (en) 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
TW200817426A (en) 2006-07-21 2008-04-16 Taiho Pharmaceutical Co Ltd 2'-cyanopyrimidine nucleoside compound
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
PL2148676T3 (pl) * 2007-04-25 2016-12-30 Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
US8124593B2 (en) * 2007-11-05 2012-02-28 Cyclacel Limited Methods of treatment using sapacitabine
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
WO2009129120A2 (en) 2008-04-15 2009-10-22 Rfs Pharma, Llc Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
US7863255B2 (en) 2008-04-29 2011-01-04 Taiho Pharmaceutical Co., Ltd. Methods of administering antitumor agent comprising deoxycytidine derivative
GB0808359D0 (en) 2008-05-08 2008-06-18 Cyclacel Ltd Process
EP2431376B2 (de) 2009-05-15 2024-02-07 Delta-Fly Pharma, Inc. Neuer stabiler kristall aus 1-(2'-cyan-2'-desoxy-beta-d-arabinofuranosyl)cytosin-monohydrochlorid
JP5610718B2 (ja) 2009-07-10 2014-10-22 三菱重工業株式会社 原子炉容器の管台作業システム
WO2011067588A1 (en) 2009-12-04 2011-06-09 Generics [Uk] Limited Cyclic sulphinyl esters of cytidine
WO2011104540A1 (en) 2010-02-24 2011-09-01 Generics [Uk] Limited One step process for the preparation of capecitabine

Also Published As

Publication number Publication date
EP2101790A1 (de) 2009-09-23
US8349792B2 (en) 2013-01-08
JP2010527908A (ja) 2010-08-19
EP2101790B1 (de) 2011-09-07
JP5457196B2 (ja) 2014-04-02
CN101610776A (zh) 2009-12-23
US20130196938A1 (en) 2013-08-01
US20100069291A1 (en) 2010-03-18
WO2008075042A1 (en) 2008-06-26
GB0625283D0 (en) 2007-01-24

Similar Documents

Publication Publication Date Title
HRP20200696T1 (hr) Terapija u kombinaciji s inhibitorom topoizomeraze
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
ATE523200T1 (de) Kombination mit sapacitibin (2'-cyano-2'-desoxy- n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosin) und einem zytotoxischen mittel
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
MXPA05004919A (es) Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
AR018166A1 (es) Productos utilizables en el tratamiento de tumores, una composicion farmaceutica y el uso de una antraciclina sola o con un inhibidor de topoisomerasa iantineoplasico en la preparacion de medicamentos
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
GB0328180D0 (en) Combination
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
WO2008051421A3 (en) Peptide-cytotoxic conjugates
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
ATE418333T1 (de) Kombination aus docetaxel und einem cdk-hemmer
IL197769A (en) The history of morphine, medicinal preparations containing them and their use in the preparation of pain medication
MXPA05004920A (es) Combinacion que comprende un inhibidor cdk y cisplatin.
WO2007146375A3 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer
MXPA04009012A (es) Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer.
WO2007144889A3 (en) Treatment of neurofibromatosis
WO2007054725A3 (en) Combination of a cdk-inhibitor and a hdac-inhibitor
WO2010022277A3 (en) Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2101790

Country of ref document: EP